LOS ANGELES, Jan. 7, 2014 /PRNewswire/ -- Kite Pharma today announced that Dr. Arie Belldegrun, Executive Chairman and Founder of Kite Pharma, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014, at 1:30 p.m. Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
(Logo: http://photos.prnewswire.com/prnh/20130513/MM13332LOGO )
About Kite Pharma
Kite Pharma, Inc. (Kite) is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system’s ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch, Kite is advancing a pipeline of proprietary eACT product candidates, both CAR and TCR products, directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are designed to provide significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. Kite’s management team has a proven track record of building successful biotechnology companies and successfully developing cutting-edge immunotherapies and oncology treatments. Kite is based in Los Angeles, CA. For more information, visit the company’s website at http://www.kitepharma.com.
Kite Contact:
Dr. Arie Belldegrun
Chief Executive Officer & Executive Chairman
(310) 824-9999
For Media:
Justin Jackson
Burns McClellan
(212) 213-0006
jjackson@burnsmc.com
For Investors:
Caitlyn Murphy
Burns McClellan
(212) 213-0006
cmurphy@burnsmc.com
SOURCE Kite Pharma, Inc.
Help employers find you! Check out all the jobs and post your resume.
